Mirikizumab
Based on 1 Customer Validation
Mirikizumab (LY3074828) is a humanized IgG4 monoclonal antibody that targets the p19 subunit of interleukin 23 (IL-23). Mirikizumab binds to human and monkey IL-23 with high affinity, with Kd values of 21 pM and 55 pM, respectively. By inhibiting the binding of IL-23 to IL-23R, Mirikizumab modulates the immune response and holds potential for research in ulcerative colitis and Crohn's disease.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.88%
- CAS No.: 1884201-71-1
- Masse moléculaire:143.74 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Human IgG4 kappa
Human
IL-23A
Mirikizumab (4.4 pM - 800 nM, 48 h) can completely neutralize IL-17A production induced by human and cynomolgus monkey IL-23 in mouse splenocytes, with IC50 values of 82 pM and 120 pM for human and cynomolgus monkey IL-23, respectively[2]. Mirikizumab (0.1 ng/mL - 1 μg/mL, 48 h) can completely inhibit IL-17 secretion induced by anti-CD3/anti-CD28 and IL-23 in two different human peripheral blood mononuclear cell (PBMC) preparations, with IC50 values of 22 μg/mL and 29 μg/mL for these PBMC preparations, respectively[2]. Mirikizumab (50 or 500 ng/mL, 48 h) does not affect IL-12-induced STAT4 phosphorylation in Kit225 and TALL-104 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Acute systemic C57BL/6 mice model
-
Dosage:7.5 mg/kg
-
Administration:Intraperitoneal injection (i.p.), dosing time of 9, 16, 32 h
-
Result:Inhibited human IL-23-induced mouse IL-17A, IL-17F, and keratin-16 mRNA production in an acute systemic mice model.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG4 kappa
ELISA, FACS, Functional assay
-
Immobilized Human IL-23 P19/IL23A Protein (mFc Tag) can bind Mirikizumab. The EC50 for this effect is 4.802 ng/mL.
Chemical Information
-
CAS No. 1884201-71-1
-
Appearance Liquid
-
Masse moléculaire 143.74 kDa
-
Color Colorless to light yellow
-
SMILES
[Mirikizumab]
-
Synonyms
LY3074828
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[2]. Steere B, et al. Generation and Characterization of Mirikizumab, a Humanized Monoclonal Antibody Targeting the p19 Subunit of IL-23. J Pharmacol Exp Ther. 2023 Nov;387(2):180-187. Steere B, Beidler C, Martin A, Bright S, Kikly K, Benschop RJ. Generation and Characterization of Mirikizumab, a Humanized Monoclonal Antibody Targeting the p19 Subunit of IL-23. J Pharmacol Exp Ther. 2023 Nov;387(2):180-187. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Mirikizumab Related Classifications
HY-P99737 Related Classifications
Powered by Bioz